

[Granules India Posts Record Revenue for a Quarter: Net Revenue of Rs. 122.40 Cr. Posted for Q3 FY'10](#)

Friday, January 22, 2010

- Revenue of Rs. 122.40 Cr, highest revenue achieved in a quarter by the Company
- Net profit of Rs 6.56 Cr
- Standalone turnover at Rs 101.34 Cr

## PRESS RELEASE

Hyderabad January 22, 2010

Granules India Ltd., a fully backward integrated formulation manufacturer, announced financial results for its fiscal year 2010 third quarter ended December 31, 2009. On a consolidated basis, Granules posted revenue of Rs. 122.40 Cr., an increase of 24.7% over the same period last year and a net profit of Rs. 6.56 Cr.

Quarter ended December 31, 2009

- Net Sales: Rs. 122.40 Cr, as compared to the same period last year at Rs. 98.14 Cr. The increase is attributed to higher production at the Company's facilities and an increase in sales within the formulation division.
- Net Profit: Rs. 6.56 Cr, as compared to the same period last year at Rs. 0.49 Cr.
- EPS: Basic EPS was Rs. 3.27 as compared to the same period last year at Rs. 0.25.

On a standalone basis, the Company achieved sales of Rs. 101.34 Cr. and a net profit of Rs. 5.87 Cr. This is the first time the standalone unit has crossed Rs. 100 Cr. in sales.

“This was a record setting quarter due to strong performance from all our divisions. I am particularly excited about our formulation division, which continues to grow rapidly and now comprises over 9% of our sales. This division will ramp up significantly over the next few quarters as we commence work on several key contracts” said C. Krishna Prasad, Managing Director of Granules.

About Granules India Ltd.,

(BSE: 532482, NSE: GRANULES)

Granules India Ltd. is a fully backward integrated formulation manufacturer. The Company is a large-scale manufacturer of Finished Dosages (FDs),

Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs), which are distributed in over 50 countries. The Company's operations and logistics expertise along with its scale allow Granules to provide customers high quality products across the pharmaceutical manufacturing value chain at a cost-effective price.

Caution Statement:

Certain statements made above may be "forward looking statements" within the meaning of applicable laws and regulations